ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links2 made here, not in the record9 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04569747A Single Arm Phase II Studyof ADjuvant EndocrineTherapy, Pertuzumab, andTrastuzumab for PatientsWith Anatomic Stage IHormone Receptor-positive,HER2-positive Breast CancerDana-Farber Cancer InstitutePhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 6 · ClinicalTrials.gov record · Version of 2026-10-06Version of 2026-10-06CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSPertuzumabEntry “Pertuzumab+TRASTUZUMAB”, read …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabEntry “Pertuzumab+TRASTUZUMAB”, read …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLetrozoleEntry “ADJUVANT ENDOCRINE THERAPY”, r…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnastrozoleMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTestedExemestaneMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pertuzumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pertuzumab+TRASTUZUMAB”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 6The record itselfClinicalTrials.gov recordVersion of 2026-10-06Record change
Nov 2PertuzumabClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5TestedCurrent
Nov 2LetrozoleClaude Opus 5.5TestedCurrent
Nov 2Anastrozolemade hereClaude Opus 5.5TestedCurrent
Nov 2Exemestanemade hereClaude Opus 5.5TestedCurrent
Nov 18PertuzumabRule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleTestedAgrees
Nov 18LetrozoleRule based · role ruleTestedAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.